ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0496

Safety and Efficacy of Rituximab for Systemic Sclerosis: A Double-Blind, Parallel-Group Comparison, Investigators Initiated Confirmatory Randomized Clinical Trial (DESIRES Study)
Abstract Number: 0831

Safety and Efficacy of Tofacitinib vs TNF Inhibitors in RA Patients Aged 50 Years or Older with One or More Cardiovascular Risks: Results from a Phase 3b/4 Randomized Safety Trial
Abstract Number: 0397

Safety and Persistence of Monthly Intravenous Iloprost in Systemic Sclerosis
Abstract Number: 0695

Safety and Tolerability of IVIg (Octagam 10%) in Patients with Active Dermatomyositis. Results of a Randomized, Double-Blind, Placebo-Controlled Phase III Trial
Abstract Number: 0187

Safety and Tolerability of Nintedanib in Patients with Autoimmune Disease-Related Interstitial Lung Diseases: Pooled Data from the SENSCIS and INBUILD Trials
Abstract Number: 1676

Safety of Baricitinib in Japanese Patients with Rheumatoid Arthritis (RA): The 2020 Interim Report from All-case Post Marketing Surveillance in Clinical Practice
Abstract Number: 0100

Safety of COVID-19 Vaccines After First Vaccination in Patients with Rheumatic Diseases in a Patient Reported Survey
Abstract Number: 1545

Safety of JAK Inhibitor in Patients with Rheumatoid Arthritis Who Developed Reactivation of Herpes Zoster Virus After Receiving JAK Inhibitor
Abstract Number: 1688

Safety Profile of Baricitinib for the Treatment of Rheumatoid Arthritis up to 9.3 Years: An Updated Integrated Safety Analysis
Abstract Number: 1828

Safety Profile of Ixekizumab for the Treatment of Psoriatic Arthritis and Axial Spondyloarthritis up to 3 Years: An Updated Integrated Safety Analysis
Abstract Number: 0730

Safety, Tolerability, and Pharmacokinetics of an Intra-articular Corticosteroid Injection Administered 7 Days Before or After Intra-articular Lorecivivint Injection into the Same Knee of Healthy Volunteers: An Open-Label, Parallel-Arm Study
Abstract Number: 1689

Safety, Tolerability, Pharmacokinetics, Receptor Occupancy, and Suppression of T-cell-Dependent Antibody Response in a Phase 1 Study with KPL-404, an anti-CD40 Monoclonal Antibody
Abstract Number: 0300

Salivary Gland Epithelial Cells Transcriptomic Analysis Highlight Their Potential Involvement in Extracellular Matrix Modification in Sjögren’s Syndrome
Abstract Number: 0002

Salivary Sodium Levels in the Parotid Salivary Gland of SS Patients Suggest B-cell Mediated Epithelial Sodium Channel Disruption
Abstract Number: 1013

SARS-CoV-2 Antibody Phenotype and Immune Gene Expression in Multi-system Inflammatory Syndrome in Children

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].